Pharmaceuticals company Bajaj Healthcare announced Q2FY25 results Revenue from Operations: Rs 1,330.9 million compared to Rs 1,012.1 million, change 31.5% YoY. EBITDA: Rs 245.2 million compared to Rs 189.5 million, change 29.4% YoY. EBITDA Margin: 18.4% for Q2FY25. PAT: Rs 94.6 million compared to Rs -34.6 million. PAT Margin: 7.1% for Q2FY25. Anil Jain, Managing Director, said: “I am delighted to present the impressive results of our second quarter for FY25. Our revenue from operations surged by approximately 32% YoY led by robust performance across all segments this coupled with expansion in our margins resulted in a 90% year-onyear increase in our bottom line from our continuing operations. We continue to undertake all efforts to sell the assets from the discontinued operations and to use the proceeds for further debt repayment and minimize the losses from the discontinued operations. We have materially repaid our borrowings to the tune of Rs 1,500 million and this has further strengthened our financial position. Contribution from our API and Formulation segments rose, with both registering strong growth at 19% and 28%, respectively. The domestic demand has remained quite encouraging and has been a source of strength even as export markets are still largely wrestling sticky inflation and elevated freights. Another key highlight was the exceptional performance of our Opium Processing business, which grew multi-fold year-on-year. The segment has quickly become a meaningful growth driver for our overall business. We are focused on expanding capacity to meet increasing government requirements and sustain its high growth trajectory going forward. Our new development and supply agreement with a European partner for an Active Pharmaceutical Ingredient (API) underscores our commitment to maintaining the highest standards of quality, as evidenced by our adherence to Good Manufacturing Practices. This also presents us with a fascinating opportunity to showcase our development capabilities and further strengthen our CDMO business. It pleases me to report that we successfully completed an approximately Rs 2,050 million fund raise denoting the strong investor belief in our company’s abilities and our upcoming growth journey. We are now firmly on the path to maintaining profitability on an overall basis and look to carry forward this positive momentum from our recent performances.” Result PDF